Record Q3 revenue $48.3M (+63% YoY); tightens FY23 guidance to $160-165M

Xeris Biopharma Holdings, Inc.

2023-Q3 EPS reported -$0.36 revenue$119,524,000

Total revenue $48.3M, up 63% YoY and 27% QoQ; product revenue $41.7M, up 41% YoY.
Gvoke net revenue $17.7M (+30% YoY); 58k prescriptions, 31% retail TRx glucagon share.
Recorlev net revenue $8.1M (+$5.6M vs prior year); patients on therapy up 203%.
Cash, cash equivalents and short-term investments $66.0M; expects cash flow breakeven in Q4 2023.
Tightened full-year 2023 revenue guidance from $155-165M to $160-165M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Xeris Biopharma Holdings, Inc. reported the three and nine months ended September 30, 2023 results: revenue $48,320, net income Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi, EPS ($0.09) per share; ($0.36) per share. Guidance raised.

Period: the three and nine months ended September 30, 2023
Revenue: $48,320
Net income: Net Loss was $12.2 million, or $0.09 per share, for the three months ended September 30, 2023 and a net loss of $48.9 mi
EPS: ($0.09) per share; ($0.36) per share
Guidance: raised
Result: reported results

Exact text from the filing

15,865 13,371 2,494 18.7 Recorlev 8,097 2,520 5,577 nm Product revenue, net 41,697 29,554 12,143 41.1 Royalty, contract and other revenue 6,623 171 6,452 nm Total revenue $ 48,320 $ 29,725 $ 18,595 62.6 nm - not meaningful Commercial Products • Gvoke® : Third quarter 2023 net revenue was $17.7 million as compared to $13.7 million in the third quarter of

View on SEC.gov

Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-23-000136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.